To Compare the changes in Neurocognitive profile in patients suffering with schizophrenia on treatment with Aripiprazole and Olanzapine
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2021/05/033511
- Lead Sponsor
- Government Medical College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
. Patient or nominated representative willing for consent
2. Patient in age group of 18-50years
3. Patients diagnosed with schizophrenia according to DSM 5 criteria with total duration
of illness less than 5 years
4. Patients who have never received aripiprazole and/or olanzapine in the past
Patients with Treatment Resistant Schizophrenia (TRS)
2. Patients with neurological disorders â?? head injury, tumours, movement disorders
(except antipsychotic induced), dementia, organic brain syndromes (eg. delirium,
amnesia), epilepsy.
3. Patients who have received ECT in past 3 months
4. Patients with co-morbid substance dependence (except nicotine and Caffeine)
5. Patients who are lactating or pregnant
6. Patients who received cognitive remediation in recent past.
7. Patients diagnosed with any unstable medical (hypothyroidism, diabetes insipidus,
kidney disease, myasthenia gravis, chronic heart disease) or surgical disorders.
8. Patients with subnormal intelligence.
9. Actively Suicidal patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method